Download PDF
CC BY 4.0 · TH Open 2021; 05(03): e230-e238
DOI: 10.1055/s-0041-1731309
Original Article

Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease

Oliver Buchhave Pedersen 
1   Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
,
Anne-Mette Hvas
1   Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Hans Beier Ommen
4   Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
,
Steen Dalby Kristensen
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Erik Lerkevang Grove 
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Patients with essential thrombocythemia (ET) and coronary artery disease (CAD) have increased risk of thromboembolic complications. In addition, a reduced antiplatelet effect of aspirin has been demonstrated in both patient groups. As ET is a platelet disorder, platelets may be more important for the thromboembolic risk in ET than in CAD. We aimed to investigate the antiplatelet effect of aspirin and platelet turnover in ET versus CAD patients.

Methods We included 48 ET patients and an age-matched group of 48 CAD patients. The effect of aspirin was evaluated by thromboxane B2 (TXB2) levels and platelet aggregation. Platelet turnover was assessed by immature platelet count (IPC) and immature platelet fraction (IPF).

Results ET patients had reduced effect of aspirin compared with CAD patients, demonstrated by significantly higher TXB2 levels (median of differences = 22.3 ng/mL, p < 0.0001) and platelet aggregation (median of differences = 131.0 AU*min, p = 0.0003). Furthermore, ET patients had significantly higher IPC (p < 0.0001) and IPF (p = 0.0004) than CAD patients.

Conclusion ET patients have lower 24-hour antiplatelet effect of aspirin than CAD patients. This may be explained by an increased platelet production and turnover counteracting the antiplatelet effect of aspirin. These findings strengthen the rationale for exploring novel antiplatelet regimens in ET patients to reduce the risk of cardiovascular events.

Keywords

aspirin - essential thrombocythemia - platelet aggregation - thromboxane B2 - platelet activation - platelet function test - coronary artery disease

Competing Interests

None related to this manuscript. The authors report the following general conflicts:


ELG has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, MSD, Mundipharma, Portola Pharmaceuticals, and Roche. He is an investigator in the SATELLITE, FLAVOUR, and ETESIAN studies (AstraZeneca) and has received unrestricted research grants from Boehringer Ingelheim. SDK has received lecture fees from Aspen and AstraZeneca. AMH has received speaker's fees from CSL Behring, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, and Leo Pharma and unrestricted research support from Octapharma, and CSL Behring. OBP and HBO have no conflicts to declare.




Publication History

Received: 02 February 2021

Accepted: 16 April 2021

Article published online:
04 July 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 94 (01) 133-143
    CrossrefPubMedGoogle Scholar
  • 2 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 3 Pascale S, Petrucci G, Dragani A. et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119 (15) 3595-3603
    CrossrefPubMedGoogle Scholar
  • 4 Carobbio A, Thiele J, Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
    CrossrefPubMedGoogle Scholar
  • 5 Dragani A, Pascale S, Recchiuti A. et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115 (05) 1054-1061
    CrossrefPubMedGoogle Scholar
  • 6 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195-198
    CrossrefPubMedGoogle Scholar
  • 7 Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167 (15) 1593-1599
    CrossrefPubMedGoogle Scholar
  • 8 Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012; 129 (01) 91-94
    CrossrefPubMedGoogle Scholar
  • 9 Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107 (11) 4214-4222
    CrossrefPubMedGoogle Scholar
  • 10 Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68 (06) 1213-1217
    CrossrefPubMedGoogle Scholar
  • 11 Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta J, Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost 2015; 114 (03) 459-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Würtz M, Hvas AM, Jensen LO. et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175 (02) 274-279
    CrossrefPubMedGoogle Scholar
  • 13 Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011; 150 (01) 39-44
    CrossrefPubMedGoogle Scholar
  • 14 Rocca B, Santilli F, Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10 (07) 1220-1230
    CrossrefPubMedGoogle Scholar
  • 15 Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med 2019; 381 (22) 2135-2144
    CrossrefPubMedGoogle Scholar
  • 16 De Stefano V, Rocca B, Tosetto A. et al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J 2018; 8 (06) 49
    CrossrefPubMedGoogle Scholar
  • 17 McBane II RD, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis 2014; 37 (02) 148-154
    CrossrefPubMedGoogle Scholar
  • 18 Guthikonda S, Alviar CL, Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (09) 743-749
    CrossrefPubMedGoogle Scholar
  • 19 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99 (05) 930-935
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99 (11) 7634-7639
    CrossrefPubMedGoogle Scholar
  • 21 Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Revised 4th Edition ed. Lyon, France: International Agency for Research on Cancer (IARC); 2017
    Google Scholar
  • 22 Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96 (06) 781-788
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Larsen ML, Pedersen OH, Hvas AM. et al. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets 2019; 30 (03) 322-328
    CrossrefPubMedGoogle Scholar
  • 24 Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)?. Eur Heart J 2007; 28 (14) 1673-1675
    CrossrefPubMedGoogle Scholar
  • 25 Frelinger AL, Li Y, Linden MD. et al. Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6 (12) 2035-2044
    CrossrefPubMedGoogle Scholar
  • 26 Würtz M, Hvas AM, Kristensen SD, Grove EL. Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res 2012; 129 (01) 56-61
    CrossrefPubMedGoogle Scholar
  • 27 Pedersen OH, Larsen ML, Grove EL. et al. Platelet characteristics in patients with essential thrombocytosis. Cytometry B Clin Cytom 2018; 94 (06) 918-927
    CrossrefPubMedGoogle Scholar
  • 28 Hanke AA, Roberg K, Monaca E. et al. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate). Eur J Med Res 2010; 15 (05) 214-219
    CrossrefPubMedGoogle Scholar
  • 29 Femia EA, Scavone M, Lecchi A, Cattaneo M. Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry. J Thromb Haemost 2013; 11 (12) 2193-2196
    CrossrefPubMedGoogle Scholar
  • 30 Gremmel T, Gisslinger B, Gisslinger H, Panzer S. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. Transl Res 2018; 200: 35-42
    CrossrefPubMedGoogle Scholar
  • 31 Petrides PE, Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis 2006; 36 (03) 379-384
    CrossrefPubMedGoogle Scholar
  • 32 Scavone M, Rizzo J, Femia EA. et al. Patients with essential thrombocythemia may be poor responders to enteric-coated aspirin, but not to plain aspirin. Thromb Haemost 2020; 120 (10) 1442-1453
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22) 2373-2383
    CrossrefPubMedGoogle Scholar
  • 34 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Giaretta A, Rocca B, Di Camillo B, Toffolo GM, Patrono C. In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease. Clin Pharmacol Ther 2017; 102 (05) 823-831
    CrossrefPubMedGoogle Scholar
  • 36 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61 (02) 314-319
    CrossrefPubMedGoogle Scholar
  • 37 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009; 53 (08) 667-677
    CrossrefPubMedGoogle Scholar
  • 38 Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013; 121 (10) 1701-1711
    CrossrefPubMedGoogle Scholar
  • 39 Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95 (04) 652-658
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Rocca B, Tosetto A, Betti S. et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136 (02) 171-182
    CrossrefPubMedGoogle Scholar
  • 41 Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost 2006; 32 (03) 251-259
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med 2017; 167 (03) 170-180
    CrossrefPubMedGoogle Scholar
  • 43 Alvarez-Larrán A, Cervantes F, Pereira A. et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116 (08) 1205-1210 , quiz 1387
    CrossrefPubMedGoogle Scholar
  • 44 Alvarez-Larrán A, Pereira A, Guglielmelli P. et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016; 101 (08) 926-931
    CrossrefPubMedGoogle Scholar
  • 45 De Stefano V, Rossi E, Carobbio A. et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J 2018; 8 (11) 112
    CrossrefPubMedGoogle Scholar
  • 46 Michiels JJ. Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. World J Crit Care Med 2015; 4 (03) 230-239
    CrossrefPubMedGoogle Scholar
  • 47 van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994; 69 (02) 81-84
    CrossrefPubMedGoogle Scholar
  • 48 Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004; 15 (02) 67-84
    CrossrefPubMedGoogle Scholar
  • 49 Nurden P, Bihour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Am J Hematol 1996; 51 (01) 79-84
    CrossrefPubMedGoogle Scholar
  • 50 Panova-Noeva M, Marchetti M, Russo L. et al. ADP-induced platelet aggregation and thrombin generation are increased in essential thrombocythemia and polycythemia vera. Thromb Res 2013; 132 (01) 88-93
    CrossrefPubMedGoogle Scholar
  • 51 Würtz M, Grove EL, Wulff LN. et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010; 3 (08) 828-835
    CrossrefPubMedGoogle Scholar
  • 52 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5 (03) 490-496
    CrossrefPubMedGoogle Scholar
  • 53 Stratz C, Bömicke T, Younas I. et al. Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy. J Am Coll Cardiol 2016; 68 (03) 286-293
    CrossrefPubMedGoogle Scholar
  • 54 Grove EL, Würtz M, Hvas AM, Kristensen SD. Increased platelet turnover in patients with previous definite stent thrombosis. J Thromb Haemost 2011; 9 (07) 1418-1419
    CrossrefPubMedGoogle Scholar
  • 55 Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC. et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009; 84 (02) 102-108
    CrossrefPubMedGoogle Scholar
  • 56 Rinder HM, Schuster JE, Rinder CS, Wang C, Schweidler HJ, Smith BR. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91 (04) 1288-1294
    CrossrefPubMedGoogle Scholar
  • 57 Marcucci R, Cioni G, Giusti B. et al. Gender and anti-thrombotic therapy: from biology to clinical implications. J Cardiovasc Transl Res 2014; 7 (01) 72-81
    CrossrefPubMedGoogle Scholar
  • 58 Rubak P, Villadsen K, Hvas AM. Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res 2012; 130 (03) 420-423
    CrossrefPubMedGoogle Scholar
  • 59 Glynn MF, Mustard JF, Buchanan MR, Murphy EA. Cigarette smoking and platelet aggregation. Can Med Assoc J 1966; 95 (11) 549-553
    PubMedGoogle Scholar